In last two decades, the lipid nanocarriers have been extensively investigated for their drug
targeting efficiency towards the critical areas of the human body like CNS, cardiac region …

Background: Schizophrenia is among the major causes of disability worldwide and the
mortality from cardiovascular disease (CVD) is significantly elevated. There is a growing …

Background: Antipsychotic-induced metabolic side effects are major concerns in
psychopharmacology and clinical psychiatry. Their pathogenetic mechanisms are still not …

Background The ketogenic diet (KD) has been used in treatment-resistant epilepsy since the
1920s. It has been researched in a variety of neurological conditions in both animal models …

Objective: Schizophrenia is associated with increased risk of cardiovascular disease (CVD),
although there is variation in risk among individuals. There are indications of shared genetic …

Maternal stress is a key risk factor in neurodevelopmental disorders, which often have a sex
bias in severity and prevalence. We previously identified O-GlcNAc transferase (OGT) as a …

One of the major concerns of modern society is to identify putative biomarkers that serve as
a valuable early diagnostic tool to identify a subset of patients with increased risk to develop …

Schizophrenia is associated with increased risk for type 2 diabetes mellitus, resulting in
elevated cardiovascular risk and limited life expectancy, translated into a weighted average …

Several lines of evidence point to the key role of neurobiological mechanisms and shared
genetic background in schizophrenia and bipolar disorder. For both disorders …

The high prevalence of metabolic syndrome in persons with schizophrenia has spurred
investigational efforts to study the mechanism beneath its pathophysiology. Early psychosis …